Shilpa Drug Patent Portfolio
Shilpa owns 2 orange book drugs protected by 5 US patents Given below is the list of Shilpa's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11147817 | Pharmaceutical composition of pemetrexed | 26 Mar, 2035 | Active |
US8940786 | Non-aqueous taxane nanodispersion formulations and methods of using the same | 30 Sep, 2033 | Active |
US9308195 | Non-aqueous taxane formulations and methods of using the same | 30 Sep, 2033 | Active |
US9763880 | Non-aqueous taxane formulations and methods of using the same | 30 Sep, 2033 | Active |
US10842770 | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | 07 Aug, 2031 | Active |
Latest Legal Activities on Shilpa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Shilpa.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Year, Large Entity | 08 May, 2024 | US10842770 |
Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2023 | US9308195 |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jul, 2022 | US8940786 |
Recordation of Patent Grant Mailed
Critical
| 19 Oct, 2021 | US11147817 |
Patent Issue Date Used in PTA Calculation
Critical
| 19 Oct, 2021 | US11147817 |
Email Notification
Critical
| 30 Sep, 2021 | US11147817 |
Issue Notification Mailed
Critical
| 29 Sep, 2021 | US11147817 |
Application Is Considered Ready for Issue
Critical
| 22 Sep, 2021 | US11147817 |
Dispatch to FDC | 22 Sep, 2021 | US11147817 |
Issue Fee Payment Verified
Critical
| 20 Sep, 2021 | US11147817 |
Issue Fee Payment Received
Critical
| 20 Sep, 2021 | US11147817 |
Mail Notice of Allowance
Critical
| 01 Jul, 2021 | US11147817 |
Email Notification
Critical
| 01 Jul, 2021 | US11147817 |
Electronic Review
Critical
| 01 Jul, 2021 | US11147817 |
Notice of Allowance Data Verification Completed
Critical
| 29 Jun, 2021 | US11147817 |
Shilpa's Family Patents
Shilpa Drug List
Given below is the complete list of Shilpa's drugs and the patents protecting them.
1. Docetaxel
Docetaxel is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8940786 | Non-aqueous taxane nanodispersion formulations and methods of using the same |
30 Sep, 2033
(8 years from now)
| Active |
US9308195 | Non-aqueous taxane formulations and methods of using the same |
30 Sep, 2033
(8 years from now)
| Active |
US9763880 | Non-aqueous taxane formulations and methods of using the same |
30 Sep, 2033
(8 years from now)
| Active |
US10842770 | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
07 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Docetaxel's drug page
2. Pemetrexed
Pemetrexed is protected by 1 patent, which is still active. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11147817 | Pharmaceutical composition of pemetrexed |
26 Mar, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pemetrexed's drug page